Companies › Sedana Medical
1 active drug program in 7 registered trials: 4 Phase 3, 2 Phase 4, 1 Phase 2; Infectious disease, Metabolic and endocrine, Other, Psychiatry.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Isoflurane Glycine receptor (alpha-1/beta) positive modulator; GABA-A receptor; anion channel positive allosteric modulator; Potassium channel subfamily K member 10 opener | GLRA1, GLRB, GABRA1, GABRB2, GABRG2 | Phase 3 | Post-Intensive Care Syndrome; Diabete Mellitus; Sedation; Prevention of Delirium … | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06809218 | Isoflurane | Phase 3 | Post-Intensive Care Syndrome | Psychiatry | Nov 2024 |
| NCT04341350 | Isoflurane | Phase 3 | Prevention of Delirium | Other | Sep 2025 |
| NCT07496593 | Isoflurane | Phase 4 | Diabete Mellitus | Metabolic and endocrine | Dec 2026 |
| NCT05867472 | Isoflurane | Phase 3 | Intensive Care Units, Pediatric | Respiratory | Dec 2026 |
| NCT07000526 | Isoflurane | Phase 4 | Sedation | Other | Mar 2027 |
| NCT04415060 | Isoflurane | Phase 3 | Covid19 | Infectious disease | Jun 2027 |
| NCT06014138 | Isoflurane | Phase 2 | Acute Respiratory Distress Syndrome | Respiratory | Jul 2027 |
Ono Pharmaceutical Lipocine UCB Biopharma SRL Haisco Pharmaceutical Group SK Life Science Acacia Pharma Pharmasoft NeuroRx Seaport Therapeutics Neurodawn Pharmaceutical
Acacia Pharma Soleno Therapeutics Tiohundra BioVersys SAS Biotechnology Institute IMASD
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.